Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease  Aurelien Amiot, Jean-Charles Grimaud, Laurent.

Présentation au sujet: "Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease  Aurelien Amiot, Jean-Charles Grimaud, Laurent."— Transcription de la présentation:

1 Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease  Aurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Jerome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaud Vaysse, Anne Bourrier, Stephane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephanie Viennot, Alexandre Aubourg, Anne-Laure Pelletier, Guillaume Bouguen, Vered Abitbol, Yoram Bouhnik Aurelien Amiot, Charlotte Gagniere, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Camille Zallot, Marc-Andre Bigard, Jerome Filippi, Xavier Hebuterne, Benjamin Pariente, Maria Nachury, Pierre Desreumaux, Xavier Roblin, Emilie Del Tedesco, Anthony Buisson, Gilles Bommelaer, Carmen Stefanescu, Arnaud Boureille, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Xavier Dray, Franck Carbonnel, Philippe Seksik, Laurent Beaugerie, Jacques Cosnes, Harry Sokol, Cecilia Landman, Stephane Nancey, Gilles Boschetti, David Laharie, Florian Poullenot, Matthieu Allez, Jean-Marc Gornet, Clautilde Baudry, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephane Koch, Stephanie Viennot, Alexandre Aubourg, Laurence Picon, Anne-Laure Pelletier, Gaelle Sickersen, Guillaume Bouguen, Vered Abitbol, Stanislas Chaussade, Yoram Bouhnik, Stephane Nahon, Betsy Winkfield, Hedia Brixi-Benmansour, Rodica Gincul, Jean- Christophe Barberis, Bruno Bonaz, Christophe Michiels, Franck Zerbib, Marie Bourrier de Beauregard, Christophe Locher, Sophie Davin- Couve, Armelle Poirette, Laurence Guillem, Monica Stetiu-Mocanu, Sylvain Beorchia, Jawad Al Qaddi Aurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Jerome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaud Vaysse, Anne Bourrier, Stephane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephanie Viennot, Alexandre Aubourg, Anne-Laure Pelletier, Guillaume Bouguen, Vered Abitbol, Yoram Bouhnik Aurelien Amiot, Charlotte Gagniere, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Camille Zallot, Marc-Andre Bigard, Jerome Filippi, Xavier Hebuterne, Benjamin Pariente, Maria Nachury, Pierre Desreumaux, Xavier Roblin, Emilie Del Tedesco, Anthony Buisson, Gilles Bommelaer, Carmen Stefanescu, Arnaud Boureille, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Xavier Dray, Franck Carbonnel, Philippe Seksik, Laurent Beaugerie, Jacques Cosnes, Harry Sokol, Cecilia Landman, Stephane Nancey, Gilles Boschetti, David Laharie, Florian Poullenot, Matthieu Allez, Jean-Marc Gornet, Clautilde Baudry, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephane Koch, Stephanie Viennot, Alexandre Aubourg, Laurence Picon, Anne-Laure Pelletier, Gaelle Sickersen, Guillaume Bouguen, Vered Abitbol, Stanislas Chaussade, Yoram Bouhnik, Stephane Nahon, Betsy Winkfield, Hedia Brixi-Benmansour, Rodica Gincul, Jean-Christophe Barberis, Bruno Bonaz, Christophe Michiels, Franck Zerbib, Marie Bourrier de Beauregard, Christophe Locher, Sophie Davin-Couve, Armelle Poirette, Laurence Guillem, Monica Stetiu-Mocanu, Sylvain Beorchia, Jawad Al Qaddi  Clinical Gastroenterology and Hepatology  Volume 14, Issue 11, Pages e2 (November 2016) DOI: /j.cgh Copyright © 2016 AGA Institute Terms and Conditions

2 Figure 1 Outcome measures at week 14 for vedolizumab therapy in patients with (A) Crohn’s disease and (B) ulcerative colitis. *P value less than .005 when comparing week 6 and week 14 efficacy results. Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh ) Copyright © 2016 AGA Institute Terms and Conditions

3 Figure 2 Changes in the (A) Harvey–Bradshaw Index, (B) partial ulcerative colitis disease activity index, and (C) C-reactive protein level at baseline and at weeks 6 and 14 after vedolizumab therapy was started. Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh ) Copyright © 2016 AGA Institute Terms and Conditions

4 Supplementary Figure 1 Changes according to the presence of steroid-free clinical remission at week 14 according to the (A) Harvey–Bradshaw Index, (B) partial ulcerative colitis disease activity index, and (C) C-reactive protein level at baseline and at weeks 6 and 14 after vedolizumab therapy was started. Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh ) Copyright © 2016 AGA Institute Terms and Conditions